TOOLS AND RESOURCES
CARE project resources
CARE Datasets
Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity
This report describes the most relevant results of screening a drug repurposing library consisting of ~5500 FDA-approved drugs and clinical candidates that have passed phase I studies for activity against SARS-CoV-2.
Public dataset, available on Zenodo. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Screening of ~7000 coronavirus-specific compounds for anti-SARS-CoV-2 activity
This report describes the most relevant results of screening selected compounds with potential activity against SARS-CoV-2 in a VeroE6 cell-based anti-SARS-CoV-2 assay.
Public dataset, available on Zenodo. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Screening of 67 compounds with predicted biosignature profile similar to remdesivir for anti-SARS-CoV-2 activity
This report describes the most relevant results of screening compounds with a similar predicted biosignature as remdesivir in a VeroE6 cell-based anti-SARS-CoV-2 assay.
Public dataset, available on Zenodo. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Screening of 452 hit enrichment compounds for anti-SARS-CoV-2 activity
This report describes the most relevant results of screening compounds with a similar predicted biosignature as remdesivir in a VeroE6 cell-based anti-SARS-CoV-2 assay.
Public dataset, available on Zenodo. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Virtual screening of 2629 Janssen compounds against SARS-CoV-2 RdRP
This report describes the most relevant results of virtually screening the Janssen Pharmaceutica compound collection for potential activity against SARS-CoV-2 RdRP and confirmation of potential hits in a VeroE6 cell-based anti-SARS-CoV-2 assay.
Public dataset, available on Zenodo. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Virtual screening of the Enamine REAL database against SARS-CoV-2 RdRP
This report describes the most relevant results of virtually screening the Enamine REAL database for potential activity against SARS-CoV-2 RdRP and confirmation of potential hits in a VeroE6 cell-based anti-SARS-CoV-2 assay.
Public dataset, available on Zenodo. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Virtual screening of the Janssen compound collection against SARS-CoV-2 Mpro
This report describes the most relevant results of virtually screening the Janssen Pharmaceutica compound collection for potential activity against SARS-CoV-2 Mpro and confirmation of potential hits in a VeroE6 cell-based anti-SARS-CoV-2 assay.
Public dataset, available on Zenodo. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Virtual screening on SARS-CoV-2 Nsp14_testing of 5474 hits in a Nsp14 biochemical assay and an A549-hACE2 SARS-CoV-2 infected cells
This report describes the most relevant results of virtually screening the Janssen Pharmaceutica compound collection for potential activity against SARS-CoV-2 Nsp14 and confirmation of potential hits in a SARS-CoV-2 Nsp10/Nsp14 biochemical exonuclease assay and in a A549-hACE2 cell-based anti-SARS-CoV-2 assay. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Virtual screening on Nsp16: screening of 1084 compounds in VeroE6-eGFP cells
This report describes the most relevant results of virtually screening the Janssen Pharmaceutica compound collection for potential activity against SARS-CoV-2 Nsp16 and confirmation of potential hits in a VeroE6 cell-based anti-SARS-CoV-2 assay. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Screening of 2694 RdRP virtual screening hits in RdRP/Nsp7/Nsp8 biochemical assay and confirmation in cellular SARS-CoV-2 assay
This report describes the most relevant results of virtually screening the Janssen Pharmaceutica compound collection for potential activity against SARS-CoV-2 RNA polymerase and confirmation of potential hits in a biochemical SARS-CoV RTC assay and A549-hACE2 cell-based anti-SARS-CoV-2 assay. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Screening for nucleoside inhibitors of the SARS-CoV-2 RdRP
This report describes the most relevant results of screening compounds with a nucleoside analogue structure from the Janssen Pharmaceutica compound collection for potential activity against SARS-CoV-2 in a cell-based assay and nucleoside triphosphates in a radioactive filtering binding RdRP assay. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Screening of 165,988 compounds reflecting biological and chemical diversity in the Janssen Library for anti-SARS-CoV-2 activity
This report describes the most relevant results of screening a diversity set of the Janssen Pharmaceutica compound collection for potential activity against SARS-CoV-2 in a stable eGFP-expressing VeroE6 cell line infected with SARS-CoV-2. Dataset generated by Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
CARE Public deliverables
D1.1 – Duo reporter HTS assay
This report describes the development of an assay to perform both antiviral screen and toxicity counter-screen in one assay, limiting the handling of screenng assay plates.
D2.2 – A HTS assay for the RTC under a 384 well plate format
This report describes a robust Coronavirus Replication/Transcription Complex assay set-up to perform HTS campaigns under a 384 well plate formas, a universal standard in pharmaceutical companies and research laboratories.
D3.1 – A streaminlined and efficient drug discovery testing cascade for CoVs
Two drug discovery drug cascades have been developed within CARE, for different approaches: target-based and phenotypic approaches. These cascades show the critical assays that are needed to identify and validate Coronavirus antivirals.
D3.5 – 1-CARE Small Molecule system impact model
This delliverable presents the first version of the system impact model capturing the end-to-end COVID-19 antiviral development system within CARE. This model can be used to develop a preparedness strategy to safely speed up the treatment of novel coronavirus outbreaks with antivirals.
D3.8 – Analysis of targets for druggability
Not all pocckets provide a suitable environment for binding drug-like molecules. This report presents the results of a structure-based tractability approach based on Fragment Hotspot Maps applied to SARS-CoV-2 targets with publicly available structures. Document available throught the Cordis webpage.
D3.9 – Portfolio report (M6)
Report on the progress to deliver optimised small molecule candidate drugs to fight coronavirus, at month 6 (September 2020) of the project.
D3.10 – Portfolio report (M12)
Report on the progress to deliver optimised small molecule candidate drugs to fight coronavirus, at month 12 (March 2021) of the project.
D3.11 – Portfolio report (M18)
Report on the progress to deliver optimised small molecule candidate drugs to fight coronavirus, at month 18 (September 2021) of the project.
D3.12 – Portfolio report (M24)
Report on the progress to deliver optimised small molecule candidate drugs to fight coronavirus, at month 24 (2022) of the project.
D6.1 – Report on setting up of rodent models
A report on the mouse and hamster models to be used in CARE project to test the best antiviral candidates developped in the project. Document available throught the Cordis webpage.
D6.2 – Report on the suitability of mouse-adapted SARS-CoV-2 virus for lethal humanised ACE-2 model
SARS-CoV-2 uses human Angiotensin-Converting Enzyme (hACE2) as the entry receptor to bind and enter cells. The differences between the mouse and human receptor mean that inbred mice do not support high titre viral replication as mouse ACE2 does not effectively bind the viral spike protein. This report describes a method to modify the receptor-binding domain of the SARS-CoV-2 virus to improve binding to the mouse ACE2 receptor so that it can infect mouse cells via the mouse ACE2 receptor.
D6.3 – Report on reverse genetics system
This report describes a yeast-based synthetic genomics platform to genetically reconstruct diverse large RNA viruses, such as SARS-CoV-2. This technic facilitates rapid response to emerging viruses as it enables the real-time generation and functional characterisation of evolving RNA virus variants during an outbreak.
D7.16 – Setup of clinical trial platform: Fast track process set up
This report presents the estimate timeline for a fast-track process for submission and review of trial documents to the ethics committees and contracts to the legal departments of the CARE clinical centres. This timeframe can serves as a basis for further role out of the clinical trial platform.
D7.17 – Setup of clinical trial platform: Implementation of representation concept completed
This report summarizes the system set-up for the implementation of clinical trials within the CARE platform.
D8.3 – Initial Data Management Plan
Initial DMP of the CARE project, presenting the type of data to be generated in CARE, the databases, etc. The DMP follows the principle that reseach data are Findable, Accessible, Interoperable and Reusable (FAIR). Document available throught the Cordis webpage.
CARE public summaries
CARE_Publishable Summary_RP1
Summary of CARE main results achieved after one year of research (April 2020-March 2021).
CARE_Publishable Summary_RP2
Summary of CARE main results achieved after two year of research (April 2021-March 2022).
CARE_Publishable Summary_RP3
Summary of CARE main results achieved after three year of research (April 2022-March 2023).
IMI & COVID-19 IMI-funded projects
IMI is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
For further details please visit: imi.europa.eu
IMI has funded seven other projects fighting COVID-19 in Spring 2020:
- COVID-RED: COVID-19 infections – Remote Early Detection
- DECISION: A miniaturized disposable molecular diagnostics platform for combatting coronavirus infections
- DRAGON: Rapid and secure AI imaging based diagnosis, stratification, follow-up, and preparedness for coronavirus pandemics
- Impentri: Development of an intravenous imatinib formulation for COVID-19 acute respiratory distress syndrome (ARDS)
- KRONO: Evaluation of a production ready portable, point-of-need platform (instrument and reagents), direct from nasal swab test for the molecular diagnostic detection of COVID-19 infection
- MAD-CoV 2: Modern approaches for developing antivirals against SARS-CoV-2
- RAPID-COVID: Robust automation and point of care identification of COVID